
|Videos|June 4, 2021
Pipeline: Presbyopia treatment to finish Phase 3 late 2021
Orasis Pharmaceuticals drop in development for treating presbyopia
Advertisement
Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Self-screening for ocular surface malignancies using a smartphone
2
Johnson & Johnson invests $1B in ACUVUE contact lens manufacturing
3
Epion Therapeutics completes phase 3 trials of EpiSmart epithelium-on cross-linking for keratoconus
4
Johnson & Johnson expands ACUVUE OASYS 1-Day for Astigmatism parameter range
5





















